Company intelligence / Profile preview

NeuBio

Ownership: Private
Development stage: Other

Overview

In-silico discovery and validation of ultra-precise mRNA biomarkers for neurological diseases, aiming to reduce clinical trial failure by enabling better patient stratification and more accurate diagnostics

Therapeutic areas: Neurology
Modalities: Next-generation sequencing assayBiomarker panelDiagnostic algorithm
Industry: Molecular Diagnostics

Partnerships

Industry partnerships for candidate validation (specific partners not listed)

Beyond the preview

Go deeper on NeuBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuBio.

Explore the full profile